CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Frontiers in Aging Neuroscience

卷:11

Matthew Cooke¹  Yossi Rathner¹  David Hare²  Franklin Rosenfeldt³  Geoffrey Head³  Judy de Haan³  Con Stough⁴  Rebecca King⁴  Brendan Tan⁴  Oliver Zwalf⁴  Andrew Pipingas⁴  Madeleine Nankivell⁴  Ruchong Ou⁴  Naomi L. Perry⁴  Renee Rowsell⁴  David A. Camfield⁴  Keith Wesnes⁵  Alena Langsjoen⁶  Peter Lansjoen⁶  Helen Macpherson⁷  Matthew P. Pase⁸ 

[1] 0Department of Health and Medical Sciences, Swinburne University of Technology, Melbourne, VIC, Australia;

[2] Austin Hospital, University of Melbourne, Melbourne, VIC, Australia;

[3] Baker Heart and Diabetes Institute, Melbourne, VIC, Australia;

[4] Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia;

[5] Department of Psychology, Northumbria University, Newcastle, United Kingdom;

[6] East Texas Medical Center and Trinity Mother Francis Hospital, Tyler, TX, United States;

[7] Faculty of Health, Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC, Australia;

[8] Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia;

[9] Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, Melbourne, VIC, Australia;

[10] Wesnes Cognition Limited, Streatley on Thames, United Kingdom;

关键词: Coenzyme Q10;    Ubiquinol;    dementia;    cognitive decline;    cognition;    aging;   

DOI  :  10.3389/fnagi.2019.00103

来源: DOAJ

【 摘 要 】

Introduction: With an aging population there is an important need for the development of effective treatments for the amelioration of cognitive decline. Multiple mechanisms underlie age-related cognitive decline including cerebrovascular disease, oxidative stress, reduced antioxidant capacity and mitochondrial dysfunction. CoQ10 is a novel treatment which has the potential to improve brain function in healthy elderly populations due to established beneficial effects on mitochondrial function, vascular function and oxidative stress.Methods and Analysis: We describe the protocol for a 90-day randomized controlled trial which examines the efficacy of Ubiquinol (200 mg/day) vs. placebo for the amelioration of cognitive decline in a healthy (non-demented) elderly sample, aged 60 years and over. The primary outcome is the effect of Ubiquinol at 90 days compared to baseline on CogTrack composite measures of cognition. Additional cognitive measures, as well as measures of cardiovascular function, oxidative stress, liver function and mood will also be monitored across 30-, 60- and 90- day time points. Data analyses will involve repeated measures analysis of variance (ANOVA).Discussion: This study will be the first of its kind to provide important clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive decline in the healthy elderly with important implications for productivity and quality of life within this age group.Clinical Trial Registration: The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12618001841268).

【 授权许可】

Unknown